MicroRNA signature for HER2-positive breast and gastric cancer

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3807-3810

  Kim, Joseph ^a   Jang, Sang Geun ^a   Kwon, Sun Young ^b   Park, Young Soo ^c   Kang, Han Sung ^a   Green, Jeffrey E ^d   Kim, Hark Kyun ^a   Ro, Jungsil ^a  

^a National Cancer Center   (South Korea)

^b Dongsan Medical Center   (South Korea)

^c Asan Medical Center   (South Korea)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Gastric cancer; HER2; miR 129; miR 139

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 129; MICRORNA 139; MICRORNA 302F; MICRORNA 337; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; STOMACH CANCER; BIOSYNTHESIS; BREAST TUMOR; ENZYMOLOGY; GENETICS; HER2; METABOLISM; MIDDLE AGED; MIR-129; MIR-139; PRINCIPAL COMPONENT ANALYSIS; SIGNAL TRANSDUCTION; STOMACH TUMOR;

BREAST CANCER; GASTRIC CANCER; HER2; MIR-129; MIR-139;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84906307037     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Korkaya H and Wicha MS: HER2 and breast cancer stem cells: more than meets the eye. Cancer Res 73(12): 3489-3493, 2013.
2. Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ and Press MF: Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24(7): 1754-1761, 2013.
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase III, open-label, randomised controlled trial. Lancet 376(9742): 687-697, 2010.
4. Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL, Ren XL, Wang T, Li Q, Jin BQ, Yao LB, Wang RA, Fan DM, Chen SY, Jia LT and Yang AG: HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 141(6): 2076-2087, 2011.
5. Jacobs TW, Gown AM, Yaziji H, Barnes MJ and Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17( 7): 1983-1987, 1999.
6. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ and Green JE: miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 4 : 79-91, 2011.
7. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Yamada Y, Arao T, Nishio K, Michalowski A and Green JE: Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J 12(2): 119-127, 2012.
8. Wu J, Qian J, Li C, Kwok L, Cheng F, Liu P, Perdomo C, Kotton D, Vaziri C, Anderlind C, Spira A, Cardoso WV and Lü J: miR- 129 regulates cell proliferation by down-regulating CDK6 expression. RNA 19(12) : 1767-1780, 2013.
9. Kang M, Li Y, Liu W, Wang R, Tang A, Hao H, Liu Z and Ou H: miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through down-regulation of SOX4 expression. Int J Mol Med 32(1): 51-58, 2013.
10. Liu Y, Hei Y, Shu Q, Dong J, Gao Y, Fu H, Zheng X and Yang G: VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One 7(4): e35800-e35807, 2012.
11. Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Vlassov A, Grimmond SM and Cloonan N: miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA 19(12): 1767-1780, 2013.